Rezolute (RZLT) Preferred Stock Liabilities (2015 - 2026)
Rezolute (RZLT) reported Preferred Stock Liabilities of $483000.0 for Q1 2026, little changed on a YoY basis from $483000.0 in Q1 2025, and little changed sequentially from $483000.0 in Q4 2025.
Rezolute (RZLT) Preferred Stock Liabilities (2015 - 2026) Analysis & Trends
Rezolute (RZLT) has 9 years of Preferred Stock Liabilities data on file, last reported at $483000.0 in Q1 2026.
- For the quarter ending Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $483000.0; the trailing twelve-month figure through Mar 2026 stood at $483000.0 (changed 0.0% YoY), and the FY2025 full-year result was $468000.0, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $483000.0 in Q1 2026, from $483000.0 in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $483000.0 in Q3 2024 to a low of $395000.0 in Q1 2022.
- A 5-year average of $450647.1 and a median of $453000.0 in 2024 frame the typical range for Preferred Stock Liabilities.
- Across the five-year window, Preferred Stock Liabilities increased 13.59% in 2024 and changed 0.0% in 2025, its largest moves.
- Tracing RZLT's Preferred Stock Liabilities over 5 years: stood at $434000.0 in 2022, then increased by 1.15% to $439000.0 in 2023, then advanced by 8.66% to $477000.0 in 2024, then advanced by 1.26% to $483000.0 in 2025, then changed by 0.0% to $483000.0 in 2026.
- Business Quant data shows RZLT's Preferred Stock Liabilities at $483000.0 in Q1 2026, $483000.0 in Q4 2025, and $483000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rezolute | 31,153.77 | 31,153.77 | - | 483,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Dec 31, 2024 | 477,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | 453,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | 412,000.00 |
| Mar 31, 2023 | 447,000.00 |
| Dec 31, 2022 | 434,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 407,000.00 |
| Mar 31, 2022 | 395,000.00 |
| Dec 31, 2021 | 383,000.00 |
| Sep 30, 2021 | 371,000.00 |
| Jun 30, 2021 | 387,000.00 |